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Abstract  
 
This review investigates the effects of very low calorie diets (VLCDs) used in the 
treatment of obesity on high density lipoprotein (HDL) levels. Although the studies 
varied widely in their intervention format, duration and baseline HDL levels, it would 
appear that HDL levels usually decrease during active weight loss using a VLCD, but 
these either return to pre-VLCD levels or improve overall during the weight 
maintenance phase. More research needs to be done to determine optimal weight 
maintenance programmes and the effects of VLCDs in the short-term as well as on 
HDL levels in groups at increased risk of coronary heart disease. 
 
Introduction  
 
With the continuous rise in obesity, there has been resurgence in the use of very low 
calorie diets (VLCDs) and more research investigating the effects of such diets has 
been undertaken. VLCDs have have often been criticised for being unsafe and an 
unhealthy way to lose weight.  The current VLCDs, however, are not to be confused 
with those from the 1970’s which resulted in a number of deaths probably due to 
vitamin and mineral deficiencies and poor quality or inadequate amounts of protein 
[1,2]. VLCDs are defined as diet replacements with <800 kcal and >400 to 450 kcal/d 
[3]. There are now a number of commercially available VLCDs. 
 
Evidence from a number of reviews [3-5] clearly demonstrates that VLCDs can result 
in significant weight loss. Despite this, there are still concerns about weight regain 
following these diets as well as detrimental health effects due to the rapid weight loss 
they induce. In this review, we aim to examine the literature and to investigate the 
effects of very low calorie diets on high density lipoproteins (HDL) levels specifically. 
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Importance of HDL 
 
Obesity is commonly associated with elevated triacylglycerols, low HDL and normal 
low-density lipoproteins [6]. The low HDL observed in obesity is associated with an 
enhanced risk of atherogenesis possibly due to increased degradation and/or 
decreased production of HDL particles. Adipose cells have been shown to bind to 
HDL [7], hence increased body fat may lead to an increased uptake of HDL particles 
from circulation resulting in a reduction in plasma HDL levels [8]. On the other hand, 
an increase in HDL has been associated with decreased risk of coronary artery 
disease [9] probably due to its role in  the reverse cholesterol transport process 
where cholesterol in peripheral tissues is transported to the liver for re-use or bile 
acid synthesis, preventing the accumulation of cholesterol in the arteries [10].  HDL is 
also thought to be cardioprotective due to its antioxidant activity [11]. 
 
 
Effect of VLCD on HDL levels 
 
Several studies have investigated changes in HDL after a period of VLCD. In Table 
1, we report the findings from 5 studies in which participants underwent VLCDs for as 
little as 2 days and as long as 12 weeks. The calorie intake varied from 450-800 kcal/ 
day. One study [12] looked at the differences in ethnicity in response to a VLCD 
delivered with exercise and behavioural therapy.  Also, the gender composition of the 
studies were quite different as some studies looked at women only [12,13], while the 
other studies all included men [14-16]. Weight loss was significant in all but the 2 day 
VLCD group [13]. 
 
With the exception of the group that underwent a VLCD for 2 days [13], changes in 
HDL are reported in Table 1. HDL was significantly decreased in two of the studies 
[12,14]. Hong et al [12] investigated the differences in response between black and 
white individuals. Their findings demonstrated that there was no difference between 
these two ethnic groups for weight and HDL in response to the VLCD intervention 
(which also included behaviour therapy and exercise).  
 
Two other studies also displayed a trend for a decrease in HDL [13,16]. In the study 
by Lin et al [16], all patients underwent two weeks of an LCD followed by 12 weeks of 
VLCD. The two groups differed in the caloric intake during the VLCD period (450 vs 
 3 
800 kcal/day). Weight loss and changes in HDL were not significant between the two 
groups.   
 
Only one study reported an increase in HDL after a 9 week VLCD [15], but this was 
not significant.  
 4 
Table 1: Studies investigating the use of VLCD only 
Study N Number 
of 
Males 
Intervention Duration of 
intervention 
Weight at 
baseline 
(Kg) 
Weight at 
end of 
intervention 
(Kg) 
HDL at 
baseline 
(mmol/L) 
HDL  at 
end of 
intervention 
(mmol/L) 
Clement et 
al (2004) (a) 
21 0 800 kcal/d 28 days 94 (3.0) 88 (3.0)* 1.05 
(0.04) 
0.9 (0.03) 
Clement et 
al (2004) (b) 
8 0 650 kcal/d 2 days 120 (7.7) 119 (8) 1.4 (0.2) - 
Haugaard et 
al (2007) 
13 4 600-800 kcal/d  8 weeks 106.4 
(SE: 4.1) 
97.0 (SE: 
4.3)* 
1.3 (SE: 
0.1) 
1.2 (SE: 
0.1)* 
Hong et al 
(2005) (a) 
152 0 Black participants 
500-800 kcal/d + 
BT + Exercise  
12 weeks 105 (21) 95(28)* 1.45 
(0.39)  
1.34 (0.39)*  
Hong et al 
2005 (b) 
152 0 White participants 
500-800 kcal/d + 
BT + Exercise 
12 weeks 104 (28) 94 (25)* 1.50 
(0.34) 
1.37 (0.34)*  
Laaksonen 
et al (2003) 
20 9 800 kcal/d  9 weeks 101.3 
(12.0) 
86.4 (9.6)* 1.17 
(0.26) 
1.22 (0.18) 
Lin et al 
(2009) (a) 
 
 
66 24 1200kcal/d + 450 
kcal/d  
14 weeks (2 
weeks LCD 
followed by 12 
weeks VLCD) 
92.5 
(14.1) 
 -8.37 
(0.7)* 
1.09 
(0.20) 
 -0.26 
(0.85) 
Lin et al 66 21 1200kcal/d +  800 14 weeks (2 92.1  -8.42 1.15  -0.49 
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All values are reported as means (standard deviation) unless stated otherwise. 
N: Number of participants 
* p <0.05 compared to baseline 
 Values reported as change 
SE: standard error
(2009) (b) kcal/d weeks LCD 
followed by 12 
weeks VLCD) 
(15.6) (0.7)* (0.25) (0.85) 
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Effect of VLCD and a weight maintenance period on HDL levels 
A number of studies investigated changes in HDL after a VLCD and a weight 
maintenance period (Table 2). These studies varied in duration of VLCD (6 weeks- 9 
months), maintenance period/follow up (4 weeks – 5 years).  Energy intake for the 
VLCD varied from 400-800 kcal/d. Two studies included exercise [17,18], while three 
other studies included behaviour therapy [19-21], four studies included medication  
[22-25] and two studies investigated individuals with type 2 diabetes [21,26].  Weight 
loss was significant for all studies after the VLCD although one study (18) included 
an LCD phase before the VLCD, another study [21] included a refeeding phase 
before the measurements were taken and a third study reported BMI but not weight 
and BMI change was not reported after the period of VLCD [26]. Weight loss at the 
end of the study remained significant in 9 of the 12 studies. As mentioned previously, 
the study by Paisey et al [26] only reported BMI which did not change significantly. 
The changes in the study by Fogelholm et al [18] were more difficult to report for both 
weight and HDL as the baseline values were reported for all of the participants and 
not provided separately for each treatment group. In addition, this study did not give 
within group significance for changes in weight or HDL at follow up.  Finally, 
Apfelbaum et al [25] only report weight change from the time of randomisation after 
the VLCD to the end of the study, therefore not including the weight loss achieved 
using the VLCD. 
 
At the end of the VLCD phase, HDL was reported for 9 of the 12 studies. HDL was 
decreased in at least one of the treatments for 6 of the studies [18,20,22,23,27,28]. 
This was significant in three studies [20,22,28] and not reported in two others [18,23].  
Four studies [19,21,24,27] reported an increase in HDL after the VLCD only one of 
which was not significant [27], however, the 2 studies that report an increase in HDL 
had a period of refeeding before the measurement [19,21]. All of the studies reported 
an increase in HDL at the end of the study with the exception of Haugaard et al [28] 
and one arm in the study by Christiansen et al [17] which both showed no change in 
HDL.  The increase in HDL was significant in at least one arm of 8 [17,19-
22,24,25,27] out of the 12 studies. 
 
The study by Christiansen et al [17] report that exercise results in a significant 
improvement on HDL while the study by Fogelholm et al [18] show a similar trend, 
but the results were not significant at the 2 year follow up. 
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Delbridge et al [27], do not report a significant difference in the improvement in HDL 
at the time of follow up between the high carbohydrate and the high protein weight 
maintenance group. Also, there were no significant differences in HDL between the 
use of a placebo and Orlistat [22] or between placebo and the neuropeptide 5 
receptor antagonist MK-0557 [23] for weight maintenance, but there was a significant 
improvement in HDL when Sibutramine was used compared to placebo [25]. 
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Table 2: Studies investigating the use of VLCDs followed by a maintenance phase 
Study N Number 
of 
Males 
Intervention Duration 
of VLCD 
Total duration 
of intervention 
Weight 
at 
baseline 
(Kg) 
Weight at 
end of 
VLCD 
(Kg) 
Weight 
at end 
of study 
(Kg) 
HDL at 
baseline 
(mmol/L) 
HDL at end 
of VLCD 
(mmol/L) 
HDL  at 
end of 
study 
(mmol/L) 
Apfelbaum 
et al (1999) 
(a) 
78 18 220-800kcal/d 
followed by 
maintenance 
(hypocaloric 
balanced diet + 
placebo) 
4 (± 1 
week) 
>12 month (4 
± 1 week of 
VLCD followed 
by 12 month 
double blind 
treatment 
phase) 
105.1 
(20.3) 
97.7 
(19.7)* 
 0.5 
(5.7)† 
-  -  0.09 
(0.08) 
Apfelbaum 
et al (1999) 
(b) 
82 15 220-800kcal/d 
followed by 
maintenance 
(hypocaloric 
balanced diet + 
sibutramine) 
4 (± 1 
week) 
>12 month (4 
± 1 week of 
VLCD followed 
by 12 month 
double blind 
treatment 
phase) 
103.4 
(17.5) 
95.7 
(16.9)* 
 -5.2 
(7.5)*† 
- -  0.13 
(0.09)* 
Christiansen 
at al (2010) 
(a) 
29 15 600 kcal/d followed 
by maintenance 
(hypocaloric 
balanced diet) 
 
8 week 12 weeks (8 
weeks of 
VLCD followed 
by 4 weeks of 
maintenance) 
107.8 
(12) 
 -11.2 
kg* 
95.5 
(11)* 
1.2 (0.3) - 1.2 (0.3) 
Christiansen 
et al (2010) 
(b) 
25 13 800kcal/d +  
exercise followed 
by maintenance 
(hypocaloric 
balanced diet + 
8 week 12 weeks (8 
weeks of 
VLCD followed 
by 4 weeks of 
maintenance). 
105.8 
(15) 
 -12.1 
kg* 
93.5 
(13)* 
1.2 (0.3) - 1.3 (0.3)* 
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exercise) 
 
 
Exercise was 
performed 
over the 12 
weeks 
Delbridge et 
al (2009)(a) 
70 35 ~500-550 kcal/d 
followed by 
maintenance (high 
carbohydrate diet) 
12 
weeks 
15 months (12 
weeks VLCD; 
12 months 
maintenance) 
109.4 
(2.6) 
 -17.6 
(0.8)* 
 
 -14.3 
(2.0) * 
(n=40) 
1.2 (0.04)  
(n=65) 
 -0.015 
(0.02) 
(n=62) 
 0.21 
(0.03)*  
(n=33) 
Delbridge et 
al (2009) (b) 
71 35 ~500-550 kcal/d 
followed by 
maintenance (high 
protein diet) 
12 
weeks 
15 months (12 
weeks VLCD; 
12 months 
maintenance) 
114.0 
(3.0) 
 -17.4 
(0.7)* 
 -14.8 
(0.5)*  
(n=42) 
1.2 (0.03)  
(n=59) 
 0.003 
(0.03)  
(n=54) 
 0.19 
(0.04)*  
(n=33) 
Erondu et al 
(2007) (a) 
176 32 800 kcal/d followed 
by weight 
maintenance 
(hypocaloric diet + 
placebo) 
6 weeks 58 weeks (6 
weeks VLCD 
followed by 52 
weeks 
maintenance) 
101.5 
(15.3) 
92.3 
(13.9)* 
95.6 
(15.7)* 
1.45 
(0.34) 
1.26 (0.25) 1.48 
(0.37) 
Erondu et al 
(2007) (b) 
181 37 800 kcal/d followed 
by weight 
maintenance 
(hypocaloric diet + 
MK-0557) 
6 weeks 58 weeks (6 
weeks VLCD 
followed by 52 
weeks 
maintenance) 
98.4 
(13.8) 
89.5 
(12.7)* 
91.1 
(14.5)* 
1.41 
(0.36) 
1.22 (0.29) 1.48 
(0.40) 
Fogelholm et 
al (2000) (a) 
 
 
 
28 0 1 week LCD + 8 
weeks VLCD + 3 
weeks LCD.   
 
No increase in 
exercise 
8 weeks 12 weeks 
weight loss + 
40 weeks no 
increased 
exercise + 2 
year follow up 
92.0 
(9.8) 
80.0 
(9.5)* 
 89.7 
(9.6) 
 
(n=27) 
1.22 
(0.24) 
1.12 (0.18)  1.34 
(0.28) 
 
(n=27) 
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Fogelholm et 
al (2000) (b) 
25 0 Same weight loss 
intervention as 
above  + walking 
program targeted 
to expend 4.2 
MJ/wk 
8  
weeks 
12 weeks 
weight loss + 
40 weeks 
walking 
program (1) + 
2 year follow 
up 
92.0 
(9.8) 
78.0 
(8.8)* 
83.9 
(12.2)  
 
(n=24) 
1.22 
(0.24) 
1.12 (0.27)  1.42 
(0.35) 
 
(n=24) 
Fogelholm et 
al (2000) (c) 
27 0 Same weight loss 
intervention as 
above  + walking 
program targeted 
to expend 8.4 
MJ/wk 
8 weeks 12 weeks 
weight loss + 
40 weeks 
walking 
program (2) + 
2 year follow 
up 
92.0 
(9.8) 
78.2 
(11.6)* 
 87.4 
(15.3) 
 
(n=23) 
1.22 
(0.24) 
1.13 (0.19)  1.41 
(0.25) 
 
(n=23) 
Haugaard et 
al (2009) 
9 2 600-800 kcal/d 
followed by weight 
maintenance 
(hypocaloric 
balanced diet)  
8 weeks 32 weeks (8 
weeks VLCD + 
24 weeks 
weight 
maintenance) 
104.5  94.7 (SE: 
4.0)* 
93.5 
(SE: 
4.9)* 
1.4  1.2 (0.1)* 1.4 (0.1) 
Heinonen et 
al (2009) 
35 19 800 kcal/d  
followed by weight 
maintenance 
(hypocaloric  
balanced diet + 
placebo or Orlistat) 
8 weeks 8 months (8 
weeks VLCD + 
6 months 
weight 
maintenance) 
101.7 
(2.0) 
 
86.9 
(1.7)* 
86.6 
(1.8)* 
1.17 
(0.04) 
1.25 (0.04)* 1.23 
(0.05)* 
Paisey et al 
(2002) 
15 6 Type 2 diabetic 
patients  
 
450kcal/d for 
women or 650 
6 weeks >5 years (6 
week VLCD 
and 5 year 
follow up) 
-  - -  1.20 
(0.39) 
- 1.26 
(0.47) 
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kcal/d for men. 
 
Pekkarinen 
et al (1998) 
29 0 429 kcal/d followed 
by weight 
maintenance 
(refeeding to low-
energy food). 
 
The programme 
included 12 
sessions of 
behaviour methods 
for weight control 
8 week 52 week (8 
week VLCD + 
9 weeks 
refeeding and 
follow up at 
week 52) 
96.1 
(10.9) 
 -12.4 
(3.3)* 
 -10.7 
(7.6)* 
(n = 27) 
1.19 
(0.25) 
 -0.20 
(0.20)* 
 0.16 
(0.18)*  
(n = 26) 
Richelsen et 
al (2007) (a) 
156 76 600-800 kcal/d 
followed by weight 
maintenance 
(hypocaloric 
balanced diet + 
Placebo) 
8 weeks 38 months (8 
weeks VLCD + 
36 months 
placebo and 
hypocaloric 
diet) 
111.9 
(16.0) 
 -14.3 *  -7.2 * 1.15 
(0.26) 
 -0.07*  0.06* 
Richelsen  et 
al (2007) (b) 
153 76 600-800 kcal/d 
followed by weight 
maintenance 
(hypocaloric 
balanced diet + 
Orlistat).  
 
8 weeks 38 months (8 
weeks VLCD + 
36 months 
Orlistat and 
hypocaloric 
diet) 
110.7 
(17.9) 
 -14.5*  -9.4* 1.13 
(0.26) 
 -0.05*  0.04* 
Rolland et al 
(2009) 
14 5 ~ 550 kcal/d + 
behaviour therapy 
followed by weight 
Average 
6.9 
months 
9 months (12 
weeks - 9 
months of 
129.6 
(23.0) 
109.1 
(14.6)* 
109.1 
(14.6)* 
1.29 
(0.19) 
1.47 (0.23)* 1.47 
(0.23)* 
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Values reported as means (standard deviation) unless stated otherwise. 
N: Number of participants 
* P<0.05 compared to baseline 
SE: standard error 
 Values reported as change;  † values do not include weight lost during the VLCD
maintenance 
(refeeding, 
balanced diet and 
behaviour therapy 
VLCD followed 
by 
maintenance) 
Wing et al 
(1991) 
17 4 LCD (1000 to 1500 
kcal/d depending 
on initial body 
weight) followed by 
a VLCD 
(400kcal/d) 
followed  by weight 
maintenance 
(refeeding  to 
hypocaloric diet) + 
BT (for duration of 
the study) 
8 weeks 72 weeks (1 
month LCD 
followed by 2 
months of 
VLCD, 
followed by 
refeeding for 8 
weeks and a 
follow up after 
52 weeks) 
102.1 
(11.7)  
83.5 
(9.5)* 
 
 
93.5 
(10.4)* 
 
 
1.11 (2.3) 1.26 (0.30)* 
 
 
1.33 
(0.25)* 
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Effect of intermittent use of VLCD on HDL levels 
Five studies reported the effects of intermittent use of VLCDs on HDL (Table 3).  The 
duration of the studies varied from 14 weeks to over two years.  The energy intake 
from VLCDs ranged from 400-600kcal/d. Two studies included women only [29] and 
one study included type 2 diabetic patients only [30]. The format of the different 
interventions varied widely and are described in more detail in Table 3.  
 
Only three studies reported weight loss after the first phase of VLCD [8,21,31] and all 
three studies report a significant weight loss. Weight loss at the end of the study was 
significant for all five studies. 
 
HDL change was reported after the first phase of VLCD in all 5 studies. At this stage, 
HDL had decreased significantly in 4 studies [8,29,30] and increased in one study 
[21]. At the end of the studies, HDL was increased in at least one arm of 3 studies 
[21,30,31], only two of which were significant [21,31]. HDL decreased in at least one 
arm of 3 studies [8,29,30] none of which were significant.  
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Table 3: Studies investigating the use of VLCDs as an intermittent treatment 
Study N Number 
of Males 
Intervention Total duration of 
intervention 
Weight at 
baseline 
(Kg) 
Weight after 
1st VLCD 
(Kg) 
Weight at 
end of 
study 
(Kg) 
HDL at 
baseline 
(mmol/L) 
HDL after 
1st VLCD 
(mmol/L) 
HDL  at 
end of 
study 
(mmol/L) 
Lantz et 
al (2003)  
117 35 450kcal/d for 16 weeks, 
followed by a refeeding to a 
hypocaloric diet (minus 
500kcal/d).  
VLCD was repeated for 2 
weeks every 3rd month or   as 
soon as their body weight 
passed an individualised pre-
determined level. 
>2 years (16 
week VLCD 
followed by 3 
week refeeding  
and 2 years of 
hypocaloric diet 
with intermittent 
or on demand 
VLCD) 
113.9 
(16.2) 
 -14.9 
(CI: -15.9; -
13.9)*  
 -9.6  
(CI: -11.6; -
7.7)* 
1.2 (0.3)  -0.1 
(CI: -0.2; 
-0.07)* 
 0.2 (CI: 
0.1; 0.2)* 
Shoji et al 
(1991) 
6 0 Intermittent LCD and VLCD.  
In the 1st LCD, energy intake 
was reduced from 1440 kcal 
to 1280 kcal to 880 kcal/d. 
In the 1st and 2nd VLCD 
periods, patients consumed 
420 kcal/d. In the intermission 
period, the same 880 kcal 
meal used in the 1st LCD was 
given. In the 2nd LCD, daily 
energy intake was increased 
weekly from 880kcal to 
1280kcal or 1440kcal with the 
same menu used in the 1st 
LCD. 
14-15 weeks (3 
weeks LCD, 4 
weeks VLCD, 1 
week 
intermission, 4 
weeks VLCD, 2-
3 weeks LCD) 
105  
(range: 
69-156) 
 -12.7 
(range: 9.6-
16.0 range) 
 
 
 -18.9 
(range: 
14.3 -31.4)* 
1.10 
(SE: 
0.11)  
 
 
0.81 (SE: 
0.05)*  
 
0.95 (SE: 
0.05) 
 
 
Shoji et al 8 0 As described above  14-15 weeks (3 102  -  -18.5Kg* 1.11   0.87 0.98 (0.05) 
 15 
(1992) weeks LCD, 4 
weeks VLCD, 1 
week 
intermission, 4 
weeks VLCD, 2-
3 weeks LCD) 
(range: 
72-156) 
(0.07) (0.06)* 
 
 
Williams 
et al 
(1998) (a) 
18 9 Type 2 diabetic patients   
1,500-1,800 kcal/d diet for 20 
weeks except for a total of 20 
study days during which they 
consumed 400-600 kcal/d 
VLCD.  
Patients followed the VLCD 
for 5 consecutive days during 
week 2 and then 1 day a 
week for 15 weeks. 
20 weeks (LCD 
except for 20 
days of 
intermittent 
VLCD) 
103.5 
(16.8) 
-  -9.6  
(SE: 5.7)* 
 
(n = 16) 
1.10 
(0.20)  
(n = 16) 
1.03 
(017)* 
1.13 (0.23) 
Williams 
et al 
(1998) (b) 
18 7 Type 2 diabetic patients   
1,500-1,800 kcal/d diet for 20 
weeks except for a total of 20 
study days during which they 
consumed 400-600 kcal/d 
VLCD. 
Patients followed the VLCD 
for 5 consecutive days during 
weeks 2, 7, 12 and 17. 
20 weeks (LCD 
except for 20 
days of 
intermittent 
VLCD) 
104.8 
(13.7) 
-  -10.4 
(SE: 5.4)* 
 
(n = 15) 
1.09 
(0.17) 
 
(n = 15) 
1.00 
(0.15)* 
1.08 (0.22) 
Wing et 
al (1994) 
45 15 400-500kcal/d for weeks 1-12 
and 24-36 of the programme.  
 
During the intermittent 
48 weeks (12 
weeks VLCD, 
followed by 12 
weeks 
refeeding, and 
105.8 
(19.4) 
 - 16.0 
(5.8)* 
 
 -14.2 
(10.3)* 
 
 
1.12 
(0.21) 
1.17 
(0.23)* 
 
 
1.25 (0.3)*  
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Values are reported as means (standard deviation) unless stated otherwise. 
N: Number of participants 
* p <0.05 compared to baseline 
 Values reported as change 
CI: confidence interval; SE: standard error 
phases, refeeding to 
hypocaloric balanced diet 
(1000-1200kcal/d). 
then another 12 
weeks VLCD, 
followed by 12 
weeks 
refeeding) 
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Discussion 
Here we reviewed the limited information available about the effects of VLCDs available. The 
results suggest that although there is not always an improvement in HDL levels during active 
weight loss using a VLCD, that there often is an improvement observed during weight 
maintenance.   
 
It was interesting to see in the study by Lin et al [16] that there was no significant difference 
in weight loss and HDL between the group that consumed 450kcal/d compared to the group 
that consumed 800 kcal/d.  This is consistent with other studies that compared the use of 
diets ranging from 240-880 kcal/d and found no significant difference in weight loss for short 
(4-6weeks) and intermediate term (16-26 weeks) [32-34]. In light of this, it could be beneficial 
for patients to be allowed to consume more and minimise the sense of limitation that occurs 
when using a VLCD and use a combination of liquid diet supplemented with lean meats or 
low-starch vegetable. 
 
From the studies presented in this review, it appears that HDL initially decreases during 
weight loss treatment using VLCDs, but then increase either back to baseline levels or result 
in an overall improvement of HDL levels during weight maintenance. This bi-phasic response 
may explain the discrepancies between the studies presented here. HDL particles are 
comprised of several subfractions: HDL2, HDL3 , apolipoprotein A-I (Apo A-I), apolipoprotein 
A-II (Apo A-II) and pre-β1. HDL2, Apo A-I and pre-β1are associated with cardioprotection and 
are found to be reduced in the obesity [35]. In response to the VLCD, Shoji et al [29] 
observed that the initial decrease in HDL2 was associated with decreased lecithin cholesterol 
ester transfer protein (LCAT) (which plays an important role in the formation of HDL2 [36]) 
while Apo A-1 increased. Apo A-1 activates LCAT, which may explain the delayed 
improvement in HDL [29].  This observation is consistent with the meta-analysis by Dattilo 
and Kris-Etherton [37] that reported a decrease during active weight loss but an increase in 
HDL when weight loss was stabilised after a dietary intervention. More information, however, 
will be required to correlate weight, Apo-A1 and LCAT metabolism changes with HDL 
changes to allow a definitive comment on this parameter. 
 
It has been suggested that exercise increases HDL cholesterol. In the studies reviewed 
here, Christiansen et al displayed a significant increase in HDL. Fogelholm et al [18] showed 
a similar trend, but this was not significant at 2 years. This was probably due to the fact that 
there was no difference in the number of steps taken between the different interventions at 
the end of the study, suggesting a poor compliance to exercise. Exercise has been 
associated with increases in HDL cholesterol, although a relatively high intensity exercise is 
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required for significant changes in HDL. It is thought that the increase in HDL in response to 
exercise is due to an increase in the activity of lipoprotein lipase (which transfers lipids to 
HDL) and a reduction in the activity of hepatic lipase (which removes lipids HDL in the blood) 
[38]. It has also been suggested that the degree of change in HDL in response to exercise 
may be dependent on genetic factors [39, 40].  
 
The main concern about the use of VLCDs is the weight regain that is often observed after. 
To date, there has not been any solution to the almost inevitable long-term weight regain 
associated with weight loss in general.  While also focussing on the prevention of weight 
regain, however, it is important to also concentrate on maintaining the health benefits (i.e. 
increased HDL) associated with the initial weight loss. The study by Delbridge et al [27] was 
quite interesting where they compared a high carbohydrate to a high protein weight 
maintenance diet for a period of 12 months. Although there was a trend for an increase in 
HDL in both groups, there was no difference between the two weight maintenance diets. 
This is inconsistent with the literature where it has been shown that at 12 months, HDL 
levels are generally higher in patients who followed a high protein diet compared to a high 
carbohydrate diet [41]. The effect of the weight maintenance diet in the study by Delbridge et 
al [27] may have been blurred by the initial weight loss achieved using the VLCD, or by lack 
of compliance to the diet. 
 
The effect of medication for weight maintenance on HDL could also be interesting to 
investigate. Four studies incorporated the use of obesity medication.  One of the studies 
investigating the use of Orlistat showed no significant difference in HDL levels in the longer 
term [22] while the other study clumped their data for the placebo and Orlistat group for their 
overall analysis [24]. Erondu et al [23] did not report a significant change in HDL at 1 year 
follow up after randomisation to the neuropeptide –Y receptor agaonist MK-0557.  The study 
investigating the use of Sibutramine for weight maintenance, however, did report a long term 
improvement in HDL.  From other studies, it would appear that Sibutramine [25,42] and 
dexfenfluramine [43] may be more effective for weight maintenance after a VLCD compared 
to Orlistat [15, 22, 44] or MK-0557 [23]. More research into the effect of Sibutramine on 
weight maintenance and the benefits on HDL should be pursued. 
 
The main difficulty encountered was the heterogeneity of the studies reviewed here. There 
was a wide variety of intervention strategies, duration and baseline HDL levels (ranging from 
1.05 to 1.50 mmol/l) which makes it very difficult to reach clear conclusions and supply 
recommendations for best practice. In addition, there is a paucity of evidence for populations 
at increased risk of coronary artery disease such as type 2 diabetics, gender and different 
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ethnic groups. There is an obvious need for more research and better defined intervention 
strategies for the use of VLCDs in long term treatment. 
 
 
Conclusion 
The results from this study suggest that HDL can be improved in the longer-term by using a 
combination of a VLCD followed by a weight maintenance period using a hypocaloric diet.  
Nevertheless, the studies reviewed here are very heterogeneous and more research needs 
to be carried out to define the short term effect of weight loss on HDL levels as well as 
investigating the effects of VLCDs in groups at higher risk of coronary heart disease such as 
type 2 diabetics. 
 
Disclosure: Some of our research has been funded by LighterLife Limited UK and Professor 
Broom is the Medical Director for this company.  
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